Tesamorelin 10mg

Tesamorelin is a synthetic polypeptide analog of growth hormone-releasing hormone. This growth hormone-releasing factor (GHRF) is similar to the hormone released from the hypothalamus gland in the brain. It has a molecular weight of 5146 kg/mole.

Tesamorelin was developed by a Montreal (Canada) based company called Theratechnologies to treat lipodystrophy, a common condition in HIV-infected patients.

In November 2010, the FDA approved Tesamorelin as a treatment for HIV-associated lipodystrophy.

In two phase 3 clinical trials, Tesamorelin was proven to significantly decrease waist circumference and visceral adipose tissue (VAT) following 26 weeks of treatment. Both studies had 26-week extension phases that confirmed the maintenance of VAT improvements.

Tesamorelin potentially activates GHRH receptors in the pituitary gland. This may lead to the synthesis and release of growth hormone, which, in turn, acts on multiple cells of the body to stimulate the production of insulin-like growth factor 1 (IGF-1).

IGF-1 mediates many of the effects of the growth hormone, which in the liver include growth, inhibition of programmed cell death, glucose update, and lipolysis. Serum IGF-1 levels tend to be low in patients with obesity, diabetes, and lipodystrophy.

Pro Peptide Research Labs sells Tesamorelin for laboratory and research use only.

A clinical trial is ongoing to assess the efficacy of Tesamorelin as a therapy for peripheral nerve injury. The investigators hypothesize that Tesamorelin treatment will allow for faster and greater recovery of motor and sensory function after surgical repair of peripheral nerves.

Tesamorelin and Lipodystrophy

Lipodystrophy is a condition that causes a person to lose fat from some parts of the body while gaining it in others. It occurs in HIV patients who are being treated with antiretroviral therapy (ART). It targets the face, arms, legs, buttocks, and truncal areas.

A literature review was conducted to evaluate the efficacy and safety of Tesamorelin for the treatment of lipodystrophy associated with HIV infection. All articles published in English, and identified from data sources were evaluated, and all pertinent information was included.

The review found that Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. Tesamorelin thus provides a useful treatment option for the management of HIV-associated lipodystrophy.

Tesamorelin and Cardiovascular Disease

Clinical research suggests that heart failure and abnormal heart rhythms may be more likely in people living with HIV. Moreover, an analysis of a large healthcare database showed that HIV-infected individuals are at an increased risk of developing cardiovascular disease.

In a randomized trial involving HIV subjects, the levels of triglycerides decreased by 50mg per deciliter in the Tesamorelin group, compared with 9 mg per deciliter in the placebo group. Levels of total and HDL cholesterol also improved significantly in the Tesamorelin group.

Tesamorelin and Body Composition

Tesamorelin selectively reduced visceral adipose tissue (VAT) in a randomized, double-blind, placebo-controlled study. Other body composition parameters, including waist circumference, total fat, and lean body mass improved in the Tesamorelin vs. placebo groups.

There were no serious adverse events during the study. No significant difference in adverse events between Tesamorelin and placebo groups was observed in the rats.

Tesamorelin and Cognition

According to a study published in the Archives of Neurology, administering Tesamorelin to patients with mild cognitive impairment or healthy older adults has positive effects on cognition. The researchers recruited 152 adults for the study, of whom 137 completed it.

Tesamorelin improved executive function and, to a lesser degree, short-term verbal memory. Cognitive function improved in healthy adults, and the expected functional decline of those with mild cognitive impairment was attenuated.

Pro Peptide Research Lab sells Tesamorelin for testing and laboratory experimentation and not for human consumption.

Tesamorelin and Memory

A randomized, double-blind, placebo-controlled trial demonstrated that Tesamorelin administration has a favorable effect on verbal memory for subjects with mild cognitive impairment (MCI), who are at a high risk of progression to Alzheimer’s dementia.

Tesamorelin FAQs

Is Tesamorelin FDA approved?

The FDA has approved Tesamorelin for the treatment of lipodystrophy in subjects with HIV infection.

What is the Half-Life of Tesamorelin?

Tesamorelin has an estimated half-life of 8-10 minutes.

Does Tesamorelin have the potential to increase IGF-1?

Yes. Research has shown that Tesamorelin may have the ability to increase IGF-1 production.

Does Tesamorelin have the potential to reduce Abdominal Fat?

In a 2014 clinical trial, Tesamorelin administered for 6 months was associated with reductions in visceral fat and additionally with modest reductions in liver fat.

Tesamorelin, a GHRH analog, has been approved by the FDA for the treatment of lipodystrophy in HIV-positive patients. In multiple clinical trials, this peptide has demonstrated the potential ability to enhance cognition, improve the body’s metabolic parameters and reduce the risk of cardiovascular disease.